Abstract
Purpose:
We have reported that topical 0.15% unoprostone ophthalmic solution (UF-021) resulted in a dose-dependent improvement in the central retinal sensitivity in patients with retinitis pigmentosa (RP). The purpose of this study was to determine the changes in visual function 2-year after the end of the UF-021 treatment.
Methods:
We studied 22 eyes of 22 RP patients who had been part of the origin 24-week clinical trial of UF-021. These patients had been randomly assigned to one of the three double-blind treatments: high dose (H, two drops/dose; n=6), low dose (L, one drop/dose; n=8), and placebo (P, n=8). The therapy was terminated in all the patients after the 24 week trial. We examined the mean retinal sensitivity of four central sites using the Humphrey Field Analyzer (HFA) 10-2 program, mean deviation (MD value), and the BCVA at the start and end of the clinical trial. These parameters were also measured 120 weeks after the completion of the trial.
Results:
We studied 22 eyes of 22 RP patients who had been part of the origin 24-week clinical trial of UF-021. These patients had been randomly assigned to one of the three double-blind treatments: high dose (H, two drops/dose; n=6), low dose (L, one drop/dose; n=8), and placebo (P, n=8). The therapy was terminated in all the patients after the 24 week trial. We examined the mean retinal sensitivity of four central sites using the Humphrey Field Analyzer (HFA) 10-2 program, mean deviation (MD value), and the BCVA at the start and end of the clinical trial. These parameters were also measured 120 weeks after the completion of the trial.
Conclusions:
The retinal sensitivity in the H group was maintained even 2 years after the UF-021 therapy was stopped. This suggests a long-term preservation of the visual sensitivity by UF-021.
Keywords: 688 retina •
615 neuroprotection •
758 visual fields